Drug Trial Radar · NCT00733811
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Last checked: Nov 20, 2026Latest source record: Aug 13, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
Sep 2000
Primary completion
Jan 2008
Study completion Jan 2008
Sponsor
- Lead sponsor
- Azienda Ospedaliera V. CervelloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Changes in chelation treatment and transfusion practices, during the past two decades, have dramatically improved the prognosis of thalassemia major patients.Deferiprone (DFP) has been compared with deferoxamine (DFO), using different schedules of treatment, in the majority of the 13 clinical trials published between 1990 and 2008.No statistically significant difference was shown between these two interventions during, at most, 18 months of treatment.Three randomised trials that compared sequential DFP-DFO treatment versus DFO alone reported controversial results but this could be due to small sample sizes and short treatment duration. In fact, no trial with treatment duration longer than 18 months15, which reported on mortality, adverse events, serum ferritin concentrations, as well as costs has so far been published. This long-term sequential DFP-DFO treatment versus DFP alone treatment trial was conducted to assess the impacts of these chelation treatments on serum ferritin concentrations, mortality, adverse events, and costs in thalassemia major patients.
Conditions
- Beta-Thalassemia
- Thalassemia Major
Interventions
Deferiprone (DFP) and Deferoxamine (DFO)Drug
Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
Deferiprone (DFP)Drug
DFP alone at 75 mg/kg divided into three oral daily doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- difference between multiple observations of the serum ferritin concentrationsTime frame: five-year treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ao V. Cervello
Palermo, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.